Nearly 3 years on from her diagnosis, Lorri Veca became a regular giver – and reflects on what it means to give back to the very organisation that supported her when she needed it most.| Leukaemia Foundation
The FDA has agreed to review GSK’s request to approve Blenrep as a second-line combination treatment for multiple myeloma.| Rare Cancer News
Phase 3 trial in nearly 500 advanced disease patients found combination therapy using Blenrep more effective at extending life than Darzalex.| Rare Cancer News
About 15% relapsed in the first year and patients lived a median of 7.5 years, and without disease progression for a median of three years.| Rare Cancer News
The FDA granted regenerative medicine advanced therapy status to the CAR T-cell therapy P-BCMA-ALLO1 for hard-to-treat multiple myeloma.| Rare Cancer News
Michael Burridge candidly shares his experience living with blood cancer and the emotional and physical journey following his diagnosis with myeloma.| Leukaemia Foundation